Vitespen (Oncophage) Vaccine Shows Promising Results Against Glioma
Filed in archive Drugs, Vaccines and Therapeutics by ruth on November 17, 2006

Derived from each individual's tumor, vitespen contains the "fingerprint" of the patient's particular cancer and is designed to reprogram the body's immune system to target only cancer cells bearing this fingerprint. The vaccine is intended to leave healthy tissue unaffected and limit the debilitating side effects typically associated with traditional cancer treatments such as chemotherapy and radiation therapy.Vitespen is also on trials, and has received fast track and orphan drug designations from the Food and Drug Administration, in both metastatic melanoma (skin cancer) and renal cell carcinoma (kidney
cancer).
More details of the clinical trials from the UCSF report.[Photo: Antigenics]
Permalink: Vitespen (Oncophage) Vaccine Shows Promising Results Against Glioma
Tags:
vaccine glioma brain+tumor tumor cancer oncophage vitespen biotech oncophage+vaccine
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/42931







